Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche by Antonella Chillemi et al.
March 2017 | Volume 8 | Article 3051
PersPective
published: 20 March 2017
doi: 10.3389/fimmu.2017.00305
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Duncan Howie, 
University of Oxford, UK
Reviewed by: 
Masahide Tone, 
Cedars-Sinai Medical Center, USA 
Arian Dominic John Laurence, 
Newcastle University, UK
*Correspondence:
Alberto L. Horenstein 
alberto.horenstein@unito.it; 
Fabio Malavasi 
fabio.malavasi@unito.it
†Senior co-authors.
Specialty section: 
This article was submitted to 
Immunological Tolerance and 
Regulation, 
a section of the journal 
Frontiers in Immunology
Received: 16 December 2016
Accepted: 03 March 2017
Published: 20 March 2017
Citation: 
Chillemi A, Quarona V, Antonioli L, 
Ferrari D, Horenstein AL and 
Malavasi F (2017) Roles and 
Modalities of Ectonucleotidases in 
Remodeling 
the Multiple Myeloma Niche. 
Front. Immunol. 8:305. 
doi: 10.3389/fimmu.2017.00305
roles and Modalities of 
ectonucleotidases in remodeling  
the Multiple Myeloma Niche
Antonella Chillemi1, Valeria Quarona1, Luca Antonioli2, Davide Ferrari3,  
Alberto L. Horenstein1*† and Fabio Malavasi1*†
1 Laboratory of Immunogenetics and CeRMS, Department of Medical Sciences, University of Torino, Torino, Italy, 
2 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 3 Department of Life Science and 
Biotechnology, University of Ferrara, Ferrara, Italy
Ectoenzymes are cell surface molecules, which represent functional bridges between 
the environment and the cytoplasm. One set of ectoenzymes—CD39, CD38, CD203a, 
and CD73—leads to the generation of adenosine (ADO) by metabolizing ATP and NAD+. 
While ADO is known to control inflammation and suppress immune responses, other 
aspects of ADO function are still obscure, mainly due to its short half-life in biological 
fluids. Human multiple myeloma (MM) grows in the closed system of the bone marrow 
(BM) niche representing an ideal setting for studying ectoenzymes and their products. 
Another source of information on ectoenzyme function may derive from in vivo results 
of anti-CD38 antibody therapy in MM. Current results, obtained from in  vitro models 
and from preliminary in vivo findings, indicate that ectoenzymes produce ADO locally in 
the BM niche. Furthermore, MM cells release microvesicles (MV), which thanks to their 
molecular cargo and surface ectoenzymes may function as particulate communicators 
outside of the niche. During anti-CD38 antibody therapy, the MV carry therapeutic IgG, 
determining that the prevalent orientation of MV will be toward cells and tissues express-
ing receptors for the IgG Fc domain. The resulting picture is one where MM adopts an 
immune escape strategy based on reshaping the environmental niche. This adaptation 
is followed by actions of MV that are exerted in biological fluids and circulating immune 
cells. By coating FcRs+ cells, MV modify pericellular spaces, reproducing the metabolic 
halo generated by ectoenzymes within closed systems.
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iNtrODUctiON
The present perspective aims to highlight the contribution of adenosinergic ectoenzymes to the 
metabolic pathways that contribute to tumor growth and active immune evasion. Part of the knowl-
edge in this field has been inferred indirectly from recent findings obtained within the context of 
immune tolerance. Supporting evidence has also been from (i) in vivo studies on organ transplanta-
tion, (ii) the identification of regulatory cell subsets, and (iii) the tolerogenic substances and their 
control mechanisms. Additional and somewhat unexpected evidence came to light with the intro-
duction of innovative therapeutic drugs. The use of immunomodulators and monoclonal antibodies 
in cancer therapy revealed previously unknown facets of normal and tumor biology. For example, 
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drug resistance was first observed when it became apparent that 
cancer cells could actively eliminate most of the toxic drugs used 
in therapy. Another important result was the identification of cell 
surface molecules able to drive the production of tolerogenic sub-
stances (e.g., adenosine, ADO) and of establishing a tolerogenic 
environment (e.g., in the bone marrow, BM).
Here, we will focus our attention on a panel of enzymes local-
ized on the cell surface (hence, ectoenzymes) that are involved in 
the metabolism of ATP and NAD+. It is known that evolutionary 
pressure led to the selection of ATP and Ca2+ as an inseparable 
tandem occurring as a leitmotif in the control of life, death, and 
cellular signaling. Schematically, the original function of ATP 
was to provide energy within the cell, while Ca2+ served as a key 
second messenger for extracellular signaling via purinergic P2 
receptors (1).
The main acceptor of extracellular ATP is the ectoenzyme 
CD39 (also known as ectonucleoside triphosphate diphospho-
hydrolase 1), which metabolizes the substrate into AMP, subse-
quently taken up by CD73 (also known as ecto-5′-nucleotidase) 
and transformed into ADO. This nucleoside exerts modulatory 
effects on immune and cancer cells by binding P1 receptors (2). 
The function of ADO in inflammation has been the subject of 
extensive reviews (3).
Over their long course of the history of life, the processes of 
generating energy and cell signals have evolved to include the 
glycolytic proton (H+) acceptor NAD+. The main acceptor of 
NAD+ in the extracellular space is CD38 and CD157 (BST1) both 
are ADP-ribosyl cyclases/cyclic ADP-ribose (ADPR) hydrolases, 
although with different catalytic characteristics (4). By consum-
ing NAD+, CD38 leads to the generation of ADPR, as well as 
of a small amount of cyclic ADPR (cADPR), a Ca2+-mobilizing 
second messenger (5). Although cyclase is only a fraction (1–3%) 
of the enzymatic output of CD38, cADPR functions as a Ca2+-
modulating agent in multiple cell types (6). In the presence 
of CD203a (also known as ectonucleotide pyrophosphatase/
phosphodiesterase-1 or PC-1), NAD+ and ADPR can also serve 
as additional sources from which to generate AMP (7).
The networks involved in the metabolism of ATP and NAD+ 
are complex and heterogeneous, encompassing a panoply of solu-
ble substrates, on one side, and cell surface receptors operating 
in different tissues, on the other side. The simplicity of the basic 
elements originally devoted to the generation of energy seems at 
odds with the complexity of the receptors involved in the use of 
their products and is perhaps symptomatic of an antieconomic 
design flaw that has managed to slip past the pressures of natural 
selection.
According to current knowledge, ATP and NAD+ may be 
metabolized by distinct ectoenzymatic pathways, one relies upon 
the presence of CD39 and CD73, the second pathway depends on 
CD38, CD203a, and CD73. The presence of CD203a enables the 
two pathways to converge and both may lead to ADO as a final 
product. It is reasonable to assume that the evolutionary process, 
which leads to this result, originated from the necessity to adjust 
the metabolic demand of cells according to the available energy 
sources and new functions. One might speculate that ADO 
straddled the two roles of information and energy source as a 
regulatory mechanism in primitive organisms (8).
Adenosine is considered to have been a central metabolite 
within the intracellular (e.g., transmethylation) and extracellular 
(e.g., purinergic) biochemical pathways (9) and also represents 
a tight link to the energetic reservoir of the cell. Later, ADO 
developed as a more sophisticated regulatory system allowing 
fine-tuning of important physiological functions (10).
Such an extensive network of cytoplasmic enzymes, plasma 
membrane ectoenzymes and receptors, as well as extracellular 
or intracellular soluble products evolved in such a way as to 
make the system not operate in an all-or-nothing fashion. On 
the contrary, this intricate system is highly sensitive and capable 
of providing just the right biological effects required by a given 
tissue at a given time. The final results arise from a combination 
of the intrinsic functional characteristics of the enzymes, their 
affinity toward their substrates, and the promiscuity derived from 
a resulting sum of affinities, substrates, and actions. Adding fur-
ther complexity is the notion that the majority of ectoenzymes are 
extremely susceptible to both the cytoplasmic and extracellular 
environment. As a consequence, ectoenzyme surface expression 
can range from nil to high, and similar variations in expression 
are also seen in the counterparts of receptors for the enzymatic 
products. The quantitative modifications are of physiological 
relevance, implementing negative or positive effects as a function 
of tissue distribution or functional status.
Some steps of ADO functionality are still waiting to be 
defined, mainly as a consequence of its active metabolization 
in biological fluids, such as blood stream, considered as an 
open system. For these reasons, some hints were derived from 
diseases taken as models from which to infer conclusions valid 
in physiology.
DiseAse MODeL: HUMAN MULtiPLe 
MYeLOMA (MM)
Human MM offers an ideal setting for dissecting the action of 
the different ectoenzymes and their products. Indeed, myeloma 
grows in a BM niche where ectoenzymes are expressed. The niche 
represents a closed system, where the products of the enzymatic 
reactions are collected and accessible for medical reasons. 
Furthermore, one of these ectoenzymes (CD38) has become a 
therapeutic target of in vivo antibody therapy (11).
A few premises are necessary to understand how the BM niche 
and the cytoplasmic conditions of myeloma cells may influence 
the functions of ectoenzymes. Tumor growth demands energy; as 
a consequence, cells may become “addicted” to alternative meta-
bolic pathways, including glucose metabolism for protein, lipid, 
and nucleotide synthesis (Figure 1) (12). Tumor cells consume 
glucose at a higher rate than normal cells and secrete most of 
the glucose-derived carbon as lactate instead of oxidizing it to 
generate ATP. This phenomenon is known as the Warburg effect. 
This glycolytic phenotype is an apparently inefficient means of 
energy production as glycolysis generates two molecules of ATP 
and two of lactic acid from each molecule of glucose consumed, 
while oxidative phosphorylation (oxphos, for short) generates 
about 30 molecules of ATP from 1 molecule of glucose (8). Such a 
wasteful form of metabolism for generating ATP seems paradoxi-
cal. However, this metabolic shift likely provides advantages for 
FiGUre 1 | Model illustrating the involvement and interplay of AtP, NAD+, and adenosine (ADO) in normoxic and hypoxic conditions. Normal cells are 
characterized by a basal rate of glucose conversion to pyruvate, generating 30 ATPs by mitochondrial oxidative phosphorylation (oxphos). Tumor cells utilize 
glycolysis instead of oxphos; most of the pyruvate is catalyzed by lactate dehydrogenase A (LDH-A) to lactate producing (i) cytoplasmic NAD+, (ii) 2 ATPs, and (iii) 
protons (H+). The efflux of lactate and H+ induces acidosis in the tumor microenvironment, which in turn moderates glycolytic metabolism by hexokinase inhibition. 
Cytoplasmic NAD+ and ATP, secreted across Panx/Cxn channels or after cell lysis, are metabolized to ADO in the extracellular space. For details see text.
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proliferating tumor cells that survive under hypoxic conditions. 
First, the shift allows tumor cells to use extracellular glucose 
for ATP production, even though at low efficiency. Second, 
glucose degradation provides tumor cells with the intermediates 
needed for various biosynthetic pathways, including ribose for 
nucleotides, glycerol and citrate for lipids, and non-essential 
amino acids for proteins. These precursors derive from the tri-
carboxylic acid cycle, a biosynthetic hub that consumes, rather 
than produces ATP. The high rate of lactate produced remains 
a controversial topic in research, because most of the pyruvate 
needs to be oxidized to enhance ATP production. It is likely that 
the glycolytic flux increases enzymatic activities, creating the 
need for a system that prevents the accumulation of pyruvate 
(13). Indeed, the induction of lactate dehydrogenase A observed 
in tumor cells rapidly consumes pyruvate (14) and regenerates 
NAD+ while yielding lactate and H+ as by-products.
Pertinent to the present perspective is that this heritable 
metabolic shift adopted by the tumor leads to acidification of 
the extracellular microenvironment, leading to apoptosis of cells 
unable to survive in such extreme conditions. Another source 
of H+ in the tumor microenvironment is from the hydrolysis of 
ATP. Over time, lactate and H+ are exported from cancer cells 
into the interstitial space, where they accumulate because of 
defective blood perfusion. The result is further acidification of 
the extracellular tumor microenvironment. Acidosis can thus be 
considered as a tool selected by tumor cells to bypass in growth 
normal cells (15).
In the course of evolution, tumors have learnt to exploit weak-
nesses in the immune system, evading defenses and proliferating 
at a distance from the original neoplastic site. As in inflammatory 
lesions, the tumor environment is characterized as a locus of 
decreased pH (16, 17), which is on average 0.5 U lower than in 
normal surrounding tissues (16). This is confirmed in several dis-
ease models, including MM. MM grows in a niche localized in the 
BM, where tumor cells are secluded in a physically constrained 
three-dimensional site surrounded by different cells (where 
osteoblasts, osteoclasts, stromal cells, and mesenchymal stem 
cells are dominant). Cells are flowed by plasma fluids, which act 
FiGUre 2 | Halo generated by microvesicles (Mv) accumulation on membranes of Fcr+ cell subsets in biological fluids. For details, see text.
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as a liquid communicator among the different cell components 
(9). Plasma and cells inside the BM are aspirated for diagnostic 
and therapeutic purpose from MM patients. This makes it pos-
sible to closely track events that occur within the niche and assess 
their resulting products.
Studies from basic and clinical science have made it possible 
to delineate the different paths and processes that favor growth 
and expansion of myeloma cells. The conclusions of these studies 
are potentially transferable to other diseases (18). It is generally 
accepted that MM exploits the capacity of pH to modify the 
environment and the immune response within the context of 
the niche. This is confirmed by the observation that low pH in 
BM plasma is paralleled by (i) phenotypic modifications of the 
cells surrounding the tumor and (ii) by increased levels of locally 
produced ADO.
Hypoxia inside MM cells is exploited to reprogram cellular 
metabolism so that aerobic glycolysis can satisfy the tumor’s addi-
tional energy requirement. Hypoxia outside the MM cells helps 
to modify the nucleotide metabolism, where ATP and NAD+ 
are metabolized by the surrounding cells expressing surface 
proteins endowed with ectonucleotidase activity. Besides serving 
as signaling molecules, nucleotides are also rapidly metabolized 
by specific ectoenzymes into other active nucleotides, and then 
converted into ADO (19). ADO performs multiple functions, 
depending on the environment (16). In the immune system, ADO 
has predominantly suppressive effects and operates through the 
binding of different types of P1 receptors (10). This ultimately 
leads to a generalized anergic status of T, NK, and dendritic 
cells, which is considered to be instrumental for myeloma cells 
immune evasion.
A further effect caused by the increasing local hypoxic con-
ditions is a shift of tumor metabolism from generating ATP to 
accumulating high levels of NAD+ (20). In fact, aerobic glycolysis 
simultaneously metabolizes glucose to pyruvate, with robust 
production of NAD+ (Figure 1), which is required for cell prolif-
eration (21). This intracellular accumulation of NAD+ favors its 
transmembrane efflux from tumor cells via Cnx or Pnx1 hemi 
channels (22, 23). On one side, this efflux constitutes a unique 
system that feeds ectonucleotidases (22); on the other, it confers 
growth advantage to the cells through increased autocrine/
paracrine NAD+ signaling, also through interactions with the 
CD38 ectoenzyme on the same membrane. The metabolic halo 
formed following NAD+ efflux may also influence the action of 
CD38 localized on adjacent non-tumor cells. Thus, micromolar 
increases in extracellular NAD+ concentrations secondary to cell 
death or lysis may exert local suppressive effects through activa-
tion of purinergic P2 receptors expressed by immune cells. This 
results in the induction of cell death in cytotoxic T effectors and 
expansion of suppressor T lymphocytes (Treg) (24).
A further effect of hypoxia is obtained by working together 
with selected cytokines to modulate the adenosinergic pathways, 
privileging an alternative pathway of ADO production (9). Indeed, 
the above conditions induce expression of the ectoenzymes 
CD203a and CD73, which are re-expressed or up-modulated by 
cells involved in NAD+ degradation. This was confirmed in the 
MM niche. Indeed, BM aspirates from MM patients indicated that 
the canonical adenosinergic CD39/CD73 pathway is flanked by 
another set of ectoenzymes, which in vivo leads to the production 
of ADO, this time using NAD+ as the starting substrate (2). In 
sequence, extracellular NAD+ is metabolized by CD38, CD203a, 
and CD73, confirming observations obtained in vitro in a human 
T leukemia line (7) and in vivo in human NK cells (25).
These ectonucleotidases operate in a discontinuous fashion 
(meaning that the components of the pathway do not need to be 
expressed by the same cell), but the metabolic halo around the 
cells forms a transmission chain of reaction products. A requisite 
is that the reactions take place in a closed microenvironment, 
where the tumor and host cells are intermingled located side by 
side. As a consequence, the metabolic activities in the BM niche 
promote the local accumulation of ADO, contributing to a local 
impairment of the immune status (26).
In conclusion, the different cellular components in the niche 
harbor at least two distinct pathways (CD203a/CD73 and CD38/
CD203a/CD73), both potentially leading to the production of ADO. 
5Chillemi et al. Ectoenzymes and the Metabolic Cell Halo
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 305
The niche provides the physical proximity necessary for the genera-
tion of intermediates and products, while the halo of enzymatic prod-
ucts surrounding juxtaposing cells mechanistically guarantees the 
functional effects of ADO, whose half-life is extremely short in vivo.
Multiple myeloma patients are characterized by a generalized 
impairment of the immune defenses. It therefore remains to be 
seen whether the observations seen in the niche may also hold 
true outside of a closed environment.
Beyond the Halo
Similar to other tumors, MM spontaneously releases microvesi-
cles (MV) as part of a normal membrane dynamics (27). MV can 
originate from either the cell membrane or from the cytoplasm 
(28). The phenotype of membrane-derived MV is highly remi-
niscent of the cells from which they originated. Surprisingly, MV 
derived from MM cells strongly express ectoenzymes, such as 
CD38, CD39, CD73, and CD203a. A possible interpretation is 
that CD38 is expressed in a membrane domain with active or 
passive grouping of specialized enzymatic molecules. In any case, 
the upshot is that MV from MM are equipped with enzymatic 
apparata potentially capable of metabolizing both ATP and 
NAD+ to produce ADO. When derived from the cell membrane, 
MV can adhere and fuse with adjacent cells, which promote their 
egression from the MM niche and migration through tissues 
from where they eventually reach the blood circulation. Naturally 
occurring MV may adhere to cells, simply guided by their surface 
and adhesion molecules. This situation changes after treatment 
with therapeutic antibodies, when MV are coated with IgG. The 
consequence is that MV are driven as their preferred destination 
toward cells and tissues expressing FcRs with different affinities. 
MV adherence to and accumulation around cells delineates a 
pericellular space, one side formed by MV and their halo and the 
other by the membrane of the normal cells. The pericellular space 
reproduces what is seen in closed environment, with synthesis 
and use of short-lived products, as in this case with ADO (29).
An even more challenging question is what happens when 
IgG-coated MV enters a cell. These MV have a cargo of proteins, 
lipids, nucleotides, and nucleic acids, whose functional effects 
are under scrutiny. Preliminary evidence indicates that the most 
up-modulated genes concern immune response, regulation of cell 
death and apoptosis, chemotaxis, and the inflammatory response.
The identification of molecules that act as enzymes on the cell 
surface but whose final products are destined for use within the 
cytoplasm suggests that we urgently need to rethink our under-
standing of extracellular metabolism.
It is generally accepted that cells surrounded by a halo of func-
tional products can be sensed by adjacent cells, provided that the 
latter are equipped with the proper receptors. In the case of ADO, 
a marked functional difference is its limited half-life, making it act 
more like a neurotransmitter, in that it is operative only within a 
short distance from the production site. An improvement may come 
when ADO is produced in the context of a tissue or closed system, 
which facilitates the interaction among biological fluids and cells.
Is it possible that ADO functions the same way as hormones do 
and functions at sites distant from the point of origin? If so, it may 
be that they rely on MV released from the tumor cell membranes. 
The phenotype of MV is characterized by clusters of ectoenzymes 
bound for biological fluids and blood located at a distance from 
their origin. This situation significantly changes in case of in vivo 
therapy with therapeutic antibodies, when they target ectoen-
zymes (e.g., CD38 and more recently CD73) (30, 31). In this case, 
the presence of a therapeutic antibody on their surface restricts 
their final destination to all the body cell populations expressing 
FcRs (Figure 2) (32).
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